A Double-Blind, Placebo-Controlled, Ascending-Dose, Randomized Study to Evaluate the Safety, Tolerability and Effects on Cognition of AL-108 after 12 Weeks of Intranasal Administration in Subjects with Mild Cognitive Impairment

“Mini-mental state”

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267 · see citing works

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works

Current concepts in mild cognitive impairment

Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781 · see citing works

Mild cognitive impairment

Gauthier, S. G., Reisberg, ‌., Zaudig, M., Petersen, R. C., Ritchie, K. A., Broich, K., Belleville, S., Brodaty, H., Bennett, D. A., Chertkow, H. M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,920 · see citing works

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials

Grundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972 · see citing works

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial

Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · see citing works

Prevalence of mild cognitive impairment is higher in men

Petersen, R. C., Roberts, R. O., Knopman, D. S., Geda, Y. E., Cha, R. H., Pankratz, V. S., Boeve, B. F., Tangalos, E. G., Ivnik, R. J., & Rocca, W. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f11d85 · Cited by 738 · see citing works

Ginkgo biloba for Prevention of Dementia A Randomized Controlled Trial

DeKosky, S. T. (2008) · JAMA · doi:10.1001/jama.2008.683 · Cited by 671 · see citing works

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer Disease<subtitle>A Randomized Controlled Trial</subtitle>

Green, R. C. (2009) · JAMA · doi:10.1001/jama.2009.1866 · Cited by 643 · see citing works

Neuropathologic Features of Amnestic Mild Cognitive Impairment

Petersen, R. C., Parisi, J. E., Dickson, D. W., Johnson, K. A., Knopman, D. S., Boeve, B. F., Jicha, G. A., Ivnik, R. J., Smith, G. E., Tangalos, E. G., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.665 · Cited by 616 · see citing works

Pathologic Correlates of Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease

Morris, J. C., & Price, J. L. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:101 · Cited by 513 · see citing works

Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia

Jicha, G. A., Parisi, J. E., Dickson, D. W., Johnson, K., Cha, R., Ivnik, R. J., Tangalos, E. G., Boeve, B. F., Knopman, D. S., Braak, H., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.674 · Cited by 399 · see citing works

Early Detection and Differential Diagnosis of Alzheimer’s Disease and Depression with Neuropsychological Tasks

Swainson, R., Hodges, J. R., Galton, C. J., Semple, J., Michael, A., Dunn, B. D., Iddon, J. L., Robbins, T. W., & Sahakian, B. J. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051269 · Cited by 375 · see citing works

The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment

Collie, A., & Maruff, P. T. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(00)00012-9 · Cited by 329 · see citing works

Subtype of Mild Cognitive Impairment and Progression to Dementia and Death

Yaffe, K. S., Petersen, R. C., Lindquist, K. J., Kramer, J. H., & Miller, B. L. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000095427 · Cited by 324 · see citing works

Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials

Raschetti, R., Albanese, E., Vanacore, N., & Maggini, M. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040338 · Cited by 322 · see citing works

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer’s Disease

Matsuoka, Y., Jouroukhin, Y., Gray, A. J., Ma, L., Hirata‐Fukae, C., Li, H.-F., Feng, L., Lecanu, L., Walker, B. R., Planel, E., et al. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130526 · Cited by 213 · see citing works

Annual Rate and Predictors of Conversion to Dementia in Subjects Presenting Mild Cognitive Impairment Criteria Defined according to a Population-Based Study

Amieva, H., Letenneur, L., Dartigues, J., Rouch‐Leroyer, I., Sourgen, C., d'Alché-Birée, F., Dib, M., Barberger‐Gateau, P., Orgogozo, J., & Fabrigoule, C. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000077815 · Cited by 187 · see citing works

Episodic and semantic memory in mild cognitive impairment

Dudas, R. B., Clague, F., Thompson, S., Graham, K. S., & Hodges, J. R. (2005) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2004.12.005 · Cited by 177 · see citing works

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage

Matsuoka, Y., Gray, A. J., Hirata‐Fukae, C., Minami, S., Waterhouse, E. G., Mattson, M. P., LaFerla, F. M., Gozes, I., & Aisen, P. S. S. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn/31:02:165 · Cited by 161 · see citing works

NAP: Research and Development of a Peptide Derived from Activity-Dependent Neuroprotective Protein (ADNP)

Gozes, I., Morimoto, B. H., Tiong, J., Fox, A. W., Sutherland, K., Dangoor, D., Holser-Cochav, M., Vered, K., Newton, P. E., Aisen, P. S. S., et al. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00053.x · Cited by 144 · see citing works

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model

Shiryaev, N., Jouroukhin, Y., Giladi, E., Polyzoidou, E., Grigoriadis, N., Rosenmann, H., & Gozes, I. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.011 · Cited by 122 · see citing works

‘Prodromal Alzheimerʼs disease’: a more useful concept than mild cognitive impairment?

Dubois, B. (2000) · Current Opinion in Neurology · doi:10.1097/00019052-200008000-00001 · Cited by 76 · see citing works

NAP, A Neuroprotective Drug Candidate in Clinical Trials, Stimulates Microtubule Assembly in the Living Cell

Gozes, I., & Divinski, I. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018208 · Cited by 71 · see citing works

A Novel Signaling Molecule for Neuropeptide Action: Activity‐dependent Neuroprotective Protein

Gozes, I., Bassan, M., Zamostiano, R., Pinhasov, A., Davidson, A., Giladi, E., Perl, O., Glazner, G. W., & Brenneman, D. E. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07884.x · Cited by 70 · see citing works

A Randomized, Double-blind, Placebo Controlled-trial of Triflusal in Mild Cognitive Impairment

Gómez‐Isla, T., Blesa, R., Boada, M., Clarimón, J., del Ser, T., Domènech, G., Ferro, J. M., Gómez‐Ansón, B., Manubens, J. M., Martínez‐Lage, J. M., et al. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181611024 · Cited by 64 · see citing works

NAP and D-SAL: neuroprotection against the β amyloid peptide (1–42)

Gozes, I., Divinski, I., & Piltzer, I. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s3-s3 · Cited by 62 · see citing works

Activity-dependent neurotrophic factor (ADNF)

Gozes, I., & Brenneman, D. E. (1996) · Journal of Molecular Neuroscience · doi:10.1007/bf02737061 · Cited by 61 · see citing works

Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: The Alzhemedtm (Tramiprosate) experience

Saumier, D., Aisen, P. S. S., Gauthier, S. G., Vellas, B. J., Ferris, S. H., Duong, A., Suhy, J., Oh, J., Lau, W. C., Garceau, D., et al. (2009) · The journal of nutrition health & aging · doi:10.1007/s12603-009-0047-4 · Cited by 34 · see citing works

Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial

Aisen, P., Thal, L. J., Ferris, S. H., Assaid, C. A., Nessly, M. L., Giuliani, M., Lines, C., Norman, B., & Potter, W. Z. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884602 · Cited by 32 · see citing works

The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy

Zemlyak, I., Manley, N. C., Vulih, I., Cutler, A. B., Graber, K., Sapolsky, R. M., & Gozes, I. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06415.x · Cited by 24 · see citing works

Activity-dependent neuroprotective protein–derived peptide, NAP, preventing alcohol-induced apoptosis in fetal brain of C57BL/6 mouse

Sari, Y. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.11.021 · Cited by 23 · see citing works

The influence of the peptide NAP on Mac-1-deficient mice following closed head injury

Zaltzman, R., Alexandrovich, A. G., Trembovler, V., Shohami, E., & Gozes, I. (2005) · Peptides · doi:10.1016/j.peptides.2005.03.014 · Cited by 22 · see citing works

NAP protects against cyanide-related microtubule destruction

Zemlyak, I., Sapolsky, R. M., & Gozes, I. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0252-7 · Cited by 14 · see citing works

The Wechsler memory scale-III: Validity and reliability

Uttl, B., & Graf, P. (1999) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/14.8.705a · Cited by 8 · see citing works

Development and validation of neuropsychological LD subtypes with radically diverse children

Crews, K. J., Hatten, K. C., D’Amato, R. C., & Pelletier, S. L. F. (1999) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/14.1.4a · Cited by 2 · see citing works

Defeating Alzheimer's disease and other dementias: a priority for European science and society

Winblad, B., Amouyel, P., Andrieu, S., Ballard, C., Brayne, C., Brodaty, H., Cedazo-Minguez, A., Dubois, B., Edvardsson, D., Feldman, H., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00062-4 · Cited by 1,676 · see citing works

Current and Future Treatments in Alzheimer Disease: An Update

Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · see citing works

Alzheimer’s disease: Recent treatment strategies

Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547 · see citing works

Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review

Reitz, C. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/369808 · Cited by 373 · see citing works

Surface-Modified Nanocarriers for Nose-To-Brain Delivery: From Bioadhesion to Targeting

Sonvico, F., Clementino, A. R., Buttini, F., Colombo, G., Pescina, S., Stanisçuaski Guterres, S., Raffin Pohlmann, A., & Nicoli, S. (2018) · doi:10.20944/preprints201802.0077.v1 · Cited by 306 · see citing works

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70088-2 · Cited by 294 · see citing works

Tau-based therapies in neurodegeneration: opportunities and challenges

Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272 · see citing works

Tau Proteins and Tauopathies in Alzheimer’s Disease

Chong, F. P., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0574-1 · Cited by 248 · see citing works

Successful therapies for Alzheimer’s disease: why so many in animal models and none in humans?

Franco, R., & Cedazo-Minguez, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00146 · Cited by 183 · see citing works

Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review

Yu, T.-W., Lane, H., & Lin, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158208 · Cited by 182 · see citing works

Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease

Bakota, L., & Brandt, R. (2016) · Drugs · doi:10.1007/s40265-015-0529-0 · Cited by 170 · see citing works

Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks

Peng, Y., Jin, H., Xue, Y.-H., Chen, Q., Yao, S., Du, M., & Liu, S. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1206572 · Cited by 176 · see citing works

An Overview on the Clinical Development of Tau-Based Therapeutics

Medina, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041160 · Cited by 156 · see citing works

Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues

Samudra, N. P., Lane‐Donovan, C., VandeVrede, L. A., & Boxer, A. L. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168553 · Cited by 135 · see citing works

New Insights Into Drug Discovery Targeting Tau Protein

Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 133 · see citing works

Microtubule Dysfunction: A Common Feature of Neurodegenerative Diseases

Sferra, A., Nicita, F., & Bertini, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197354 · Cited by 132 · see citing works

Development of disease-modifying drugs for frontotemporal dementia spectrum disorders

Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122 · see citing works

New perspectives on the role of tau in Alzheimer's disease. Implications for therapy

Medina, M., & Ávila, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.013 · Cited by 118 · see citing works

Preventing dementia? Interventional approaches in mild cognitive impairment

Lissek, V. J., & Boris Suchan, A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.022 · Cited by 119 · see citing works

Aducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review

Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer s Disease · doi:10.1155/2022/9343514 · Cited by 119 · see citing works

Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer’s Disease: A Hypothesis

Sonawane, S. K., & Chinnathambi, S. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1111-5 · Cited by 113 · see citing works

Discovery of autism/intellectual disability somatic mutations in Alzheimer’s brains: mutated ADNP cytoskeletal impairments and repair as a case study

Ivashko-Pachima, Y., Hadar, A., Grigg, I., Korenková, V., Kapitansky, O., Karmon, G., Gershovits, M., Sayas, C. L., Kooy, R. F., Attems, J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0563-5 · Cited by 107 · see citing works

ADNP/NAP dramatically increase microtubule end-binding protein–Tau interaction: a novel avenue for protection against tauopathy

Ivashko‐Pachima, Y., Sayas, C. L., Malishkevich, A., & Gozes, I. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.255 · Cited by 102 · see citing works

Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome

Hacohen-Kleiman, G., Sragovich, S., Karmon, G., Gao, A. Y. L., Grigg, I., Pasmanik‐Chor, M., Le, A., Korenková, V., McKinney, R. A., & Gozes, I. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98199 · Cited by 101 · see citing works

Baicalein suppresses Repeat Tau fibrillization by sequestering oligomers

Sonawane, S. K., Balmik, A. A., Boral, D., Ramasamy, S., & Chinnathambi, S. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108119 · Cited by 98 · see citing works

Targeting tau: clinical trials and novel therapeutic approaches

VandeVrede, L., Boxer, A. L., & Polydoro, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134919 · Cited by 90 · see citing works

Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease

Toniolo, S., Sen, A., & Husain, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239318 · Cited by 94 · see citing works

Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory

Amram, N., Hacohen-Kleiman, G., Sragovich, S., Malishkevich, A., Katz, J., Touloumi, O., Lagoudaki, R., Grigoriadis, N., Giladi, E., Yeheskel, A., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.208 · Cited by 90 · see citing works

Repositioning Microtubule Stabilizing Drugs for Brain Disorders

Varidaki, A., Hong, Y., & Coffey, E. T. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00226 · Cited by 89 · see citing works

Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development

Cacabelos, R., Cacabelos, P., Torrellas, C., Tellado, I., & Carril, J. C. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_13 · Cited by 85 · see citing works

A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12453 · Cited by 72 · see citing works

Disease-modifying drugs in Alzheimer's disease

Scarpini, E. A., Galimberti, D., & Ghezzi, L. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s41431 · Cited by 74 · see citing works

The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse

Sragovich, S., Malishkevich, A., Piontkewitz, Y., Giladi, E., Touloumi, O., Lagoudaki, R., Grigoriadis, N., & Gozes, I. (2019) · Translational Psychiatry · doi:10.1038/s41398-018-0357-6 · Cited by 60 · see citing works

ADNP Plays a Key Role in Autophagy: From Autism to Schizophrenia and Alzheimer's Disease

Sragovich, S., Wagner, A. M., & Gozes, I. (2017) · BioEssays · doi:10.1002/bies.201700054 · Cited by 62 · see citing works

Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities

Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61 · see citing works

SH3- and actin-binding domains connect ADNP and SHANK3, revealing a fundamental shared mechanism underlying autism

Ivashko‐Pachima, Y., Ganaiem, M., Ben-Horin-Hazak, I., Lobyntseva, A., Bellaiche, N., Fischer, I., Levy, G., Sragovich, S., Karmon, G., Giladi, E., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01603-w · Cited by 58 · see citing works

Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity

Huang, Y., Wu, Z., & Zhou, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2042-8 · Cited by 58 · see citing works

The autism-mutated ADNP plays a key role in stress response

Sragovich, S., Ziv, Y., Vaisvaser, S., Shomron, N., Hendler, T., & Gozes, I. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0569-4 · Cited by 51 · see citing works

The Eight and a Half Year Journey of Undiagnosed AD: Gene Sequencing and Funding of Advanced Genetic Testing Has Led to Hope and New Beginnings

Gozes, I., Patterson, M. C., Dijck, A. V., Kooy, R. F., Peeden, J., Eichenberger, J. A., Zawacki-Downing, A., & Bedrosian‐Sermone, S. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00107 · Cited by 50 · see citing works

Diagnosis and Treatment of Alzheimer’s Disease:

Bomasang-Layno, E., & Bronsther, R. (2021) · Delaware Journal of Public Health · doi:10.32481/djph.2021.09.009 · Cited by 52 · see citing works

Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease

Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow�, E., Horn, A. H. C., Sticht, H., Malhis, M., Will, N., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167432 · Cited by 48 · see citing works

Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain

Stefanovski, L., Meier, J. M., Pai, R. K., Triebkorn, P., Lett, T. A. P., Martin, L., Bülau, K., Hofmann‐Apitius, M., Solodkin, A., McIntosh, A. R., et al. (2021) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2021.630172 · Cited by 46 · see citing works

Disentangling tau: One protein, many therapeutic approaches

Lane‐Donovan, C., & Boxer, A. L. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00321 · Cited by 44 · see citing works

Intranasal gene delivery for treating Parkinson’s disease: overcoming the blood–brain barrier

Aly, A. E.-E., & Waszczak, B. L. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.1069815 · Cited by 45 · see citing works

Diaminothiazoles Modify Tau Phosphorylation and Improve the Tauopathy in Mouse Models*

Zhang, X., Hernández, I., Rei, D., Mair, W., Laha, J. K., Cornwell, M. E., Cuny, G. D., Tsai, L., Steen, J. A. J., & Kosik, K. S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.436402 · Cited by 45 · see citing works

Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development

Bose, M., Quipildor, G. F., Ehrlich, M. E., & Salton, S. R. (2022) · Cells · doi:10.3390/cells11223629 · Cited by 44 · see citing works

Cytoskeletal Proteins and Alzheimer’s Disease Pathogenesis: Focusing on the Interplay with Tau Pathology

Jiang, G., Xie, G., Li, X., & Xiong, J. (2025) · Biomolecules · doi:10.3390/biom15060831 · Cited by 45 · see citing works

NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies

Ivashko‐Pachima, Y., Maor-Nof, M., & Gozes, I. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213666 · Cited by 40 · see citing works

Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy

Gozes, I., Gold, Lorenzl, Stewart, A. J., Morimoto, B. H., & Williams (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12518 · Cited by 39 · see citing works

Activity-Dependent Neuroprotective Protein (ADNP): A Case Study for Highly Conserved Chordata-Specific Genes Shaping the Brain and Mutated in Cancer

Gozes, I., Yeheskel, A., & Pasmanik‐Chor, M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142490 · Cited by 33 · see citing works

Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases

Morimoto, B. H., Fox, A. W., Stewart, A. J., & Gold, M. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.827403 · Cited by 33 · see citing works

Precision Medicine for Frontotemporal Dementia

Liu, M., Lau, C. I., & Lin, C. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00075 · Cited by 30 · see citing works

Davunetide sex-dependently boosts memory in prodromal Alzheimer’s disease

Gozes, I., Blatt, J., & Lobyntseva, A. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03118-0 · Cited by 27 · see citing works

Ellagic Acid: A Green Multi-Target Weapon That Reduces Oxidative Stress and Inflammation to Prevent and Improve the Condition of Alzheimer’s Disease

Alfei, S., & Zuccari, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020844 · Cited by 28 · see citing works

Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs

Logroscino, G., Imbimbo, B. P., Lozupone, M., Sardone, R., Capozzo, R., Battista, P., Zecca, C., Dibello, V., Giannelli, G., Bellomo, A., et al. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1598377 · Cited by 28 · see citing works

Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings

Duggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 28 · see citing works

Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy

Ivashko‐Pachima, Y., & Gozes, I. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.07.008 · Cited by 25 · see citing works

The Structure Biology of Tau and Clue for Aggregation Inhibitor Design

Wang, D., Huang, X., Yan, L., Zhou, L., Chang, Y., Wu, J., Su, Z., & Huang, Y. (2021) · The Protein Journal · doi:10.1007/s10930-021-10017-6 · Cited by 26 · see citing works

Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women

Gozes, I., Shapira, G., Lobyntseva, A., & Shomron, N. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02618-9 · Cited by 26 · see citing works

Developmental Phenotype of the Rare Case of DJ Caused by a Unique ADNP Gene De Novo Mutation

Levine, J., Cohen, D., Herman, C., Verloès, A., Guinchat, V., Diaz, L., Cravero, C., Mandel, A., & Gozes, I. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01333-9 · Cited by 24 · see citing works

Targeting Tau to Treat Clinical Features of Huntington's Disease

Masnata, M., Salem, S., Jacquet, A. D. R., Anwer, M., & Cicchetti, F. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.580732 · Cited by 23 · see citing works

How do neurons age? A focused review on the aging of the microtubular cytoskeleton

Richardson, B., Goedert, T., Quraishe, S., Deinhardt, K., & Mudher, A. K. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.390974 · Cited by 24 · see citing works

Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease

Ruthirakuhan, M. T., Herrmann, N., Suridjan, I., Abraham, E. H., Farber, I., & Lanctôt, K. L. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258060 · Cited by 22 · see citing works

Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy

Shoeibi, A., Olfati, N., & Litvan, I. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1460356 · Cited by 22 · see citing works

Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration

Yeboah, F., Kim, T., Bill, A., & Dettmer, U. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104543 · Cited by 22 · see citing works

Disease-modifying therapies for tauopathies: agents in the pipeline

Panza, F., Imbimbo, B. P., Lozupone, M., Greco, A., Seripa, D., Logroscino, G., Daniele, A., & Colosimo, C. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1606715 · Cited by 19 · see citing works

Sexual divergence in activity‐dependent neuroprotective protein impacting autism, schizophrenia, and A lzheimer's disease

Gozes, I. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23808 · Cited by 20 · see citing works

The next step of neurogenesis in the context of Alzheimer’s disease

Moradi, H. R., Hajali, V., Khaksar, Z., Vafaee, F., Forouzanfar, F., & Negah, S. S. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06520-9 · Cited by 20 · see citing works

Advances in the treatment and management of frontotemporal dementia

Benussi, A., & Borroni, B. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2228491 · Cited by 19 · see citing works

Targets, trials and tribulations in Alzheimer therapeutics

Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 18 · see citing works

ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration

Gozes, I., & Ivashko‐Pachima, Y. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00205 · Cited by 18 · see citing works

Microtubule Dynamics Following Central and Peripheral Nervous System Axotomy

Kulkarni, R., Thakur, A., & Kumar, H. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00189 · Cited by 16 · see citing works

Multitarget Drug Discovery Projects in CNS Diseases: Quantitative Systems Pharmacology as a Possible Path Forward

Geerts, H., & Kennis, L. E. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.97 · Cited by 16 · see citing works

Putative Blood Somatic Mutations in Post-Traumatic Stress Disorder-Symptomatic Soldiers: High Impact of Cytoskeletal and Inflammatory Proteins

Sragovich, S., Gershovits, M., Lam, J. C. K., Li, V. O. K., & Gozes, I. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201158 · Cited by 15 · see citing works

Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer’s Disease

Ivashko‐Pachima, Y., Zhou, L.-Y., Lei, P., & Gozes, I. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0715-x · Cited by 15 · see citing works

Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity

Galushkin, A., & Gozes, I. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115573 · Cited by 14 · see citing works

Drug therapies in older adults (part 1)

Mukhtar, O., & Jackson, S. H. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-1-47 · Cited by 14 · see citing works

Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration

Giunta, M., Solje, E., Gardoni, F., Borroni, B., & Benussi, A. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s262352 · Cited by 14 · see citing works

STOP Codon Mutations at Sites of Natural Caspase Cleavage Are Implicated in Autism and Alzheimer’s Disease: The Case of ADNP

Gozes, I., & Shazman, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.867442 · Cited by 13 · see citing works

Deciphering the Enigma: NAP (CP201) the Active ADNP Drug Candidate Enters Cells by Dynamin-Associated Endocytosis

Ivashko‐Pachima, Y., & Gozes, I. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01632-6 · Cited by 12 · see citing works

Tau Diagnostics and Clinical Studies

Gozes, I., Höglinger, G. U., Quinn, J. P., Hooper, N. M., & Höglund, K. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0983-0 · Cited by 12 · see citing works

Tau, ADNP , and sex

Gozes, I. (2023) · Cytoskeleton · doi:10.1002/cm.21776 · Cited by 11 · see citing works

Peptide therapeutics: current status and future opportunity with focus on nose-to-brain delivery☆

Jülke, E., & Beck‐Sickinger, A. G. (2025) · Peptides · doi:10.1016/j.peptides.2025.171404 · Cited by 13 · see citing works

Recent Advancements in Strategies for Abnormal Protein Clearance in Alzheimer's Disease

Zhuang, J., Gao, J., Yin, Y., Gong, B., Ji, W., Chen, X., Li, P., Cheng, W., Zhao, Y., & He, B. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220214092824 · Cited by 10 · see citing works

Twenty years of therapeutic development in tauopathy mouse models: a scoping review

Langness, V. F., Simmons, D. A., McHugh, T. L. M., Butler, R. R., Zhou, J., Liu, H., Yang, T., Ellerby, L., & Longo, F. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70578 · Cited by 9 · see citing works

Surface modification of nanocarriers as a strategy to enhance the direct nose-to-brain drug delivery

Pardeshi, C. V., & Souto, E. B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822522-6.00006-0 · Cited by 9 · see citing works

Unraveling the tau puzzle: a review of mechanistic targets and therapeutic interventions to prevent tau pathology in Alzheimer’s disease

Kammula, S. V., Tripathi, S., Wang, N., Dawson, V. L., Dawson, T. M., & Mao, X. (2023) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2023.20 · Cited by 9 · see citing works

Use of focused computerized cognitive training (Neuroflex) to improve symptoms in women with persistent chemotherapy-related cognitive impairment

Vega, J. N., NEWHOUSE, P. A., Conley, A. C., Szymkowicz, S. M., Gong, X., Cote, S. E., Mayer, I. A., Taylor, W. D., & Morimoto, S. S. (2023) · Digital Health · doi:10.1177/20552076231192754 · Cited by 8 · see citing works

Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches

Sayas, C. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00005-7 · Cited by 8 · see citing works

Single-cell analysis of cytoskeleton dynamics: From isoelectric focusing to live cell imaging and RNA-seq

Gozes, I., Ivashko‐Pachima, Y., Kapitansky, O., Sayas, C. L., & Iram, T. (2019) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2019.05.014 · Cited by 8 · see citing works

VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive in vivo and in silico Effects

Sragovich, S., Amram, N., Yeheskel, A., & Gozes, I. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00589 · Cited by 8 · see citing works

Glial Cells in Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Frontiers

Sil, M., Mukherjee, N., Chatterjee, I., Ghosh, A., & Goswami, A. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02379-8 · Cited by 8 · see citing works

Tau post-translational modifications in Alzheimer's disease: Insights into pathogenesis, therapeutic strategies, and diagnostic advances

Lei, H., Chen, X., Ruan, L., Liu, X., Ye, F., Li, K., Cheng, W., Yu, B., Di, C., & Di, C. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102927 · Cited by 7 · see citing works

Neuroprotective Drug Development: The Story of ADNP, NAP (Davunetide), and SKIP

Gozes, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00013-2 · Cited by 7 · see citing works

Sex-Specific ADNP/NAP (Davunetide) Regulation of Cocaine-Induced Plasticity

Toren, Y., Ziv, Y., Sragovich, S., McKinney, R. A., Barak, S., Shazman, S., & Gozes, I. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02234-2 · Cited by 5 · see citing works

Novel therapeutic approaches for targeting Alzheimer’s disease

Khodakiya, A., Chaudhary, S., Chaudhary, A., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00020-0 · Cited by 5 · see citing works

Targeted tau protein degradation: a promising therapeutic approach for tauopathies

Baazaoui, N., Alfaifi, M. Y., Shati, A. A., Saad, R. B., & Garzoli, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.11.041 · Cited by 4 · see citing works

Tau and Alzheimer’s Disease: Molecular Mechanisms and Treatment Approaches

Reiss, A. B., Muhieddine, D., Leon, A. Z. D., Voloshyna, I., Gomolin, I. H., & Pinkhasov, A. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-021-01092-y · Cited by 4 · see citing works

Comprehending Alzheimer's Disease: Molecular Mechanisms and Treatment Strategies

Rathee, S., Pandey, V., Soni, S., Sen, D., & Jain, S. (2025) · Current Alzheimer Research · doi:10.2174/0115672050368798250626075628 · Cited by 5 · see citing works

Revolutionizing Therapeutic Approaches Against Pathophysiology of Alzheimer’s Disease: A Therapeutic Review

Saini, M., Rohilla, S., & Kumar, R. (2025) · Current Aging Science · doi:10.2174/0118746098376646250715094707 · Cited by 3 · see citing works

P2‐377: A phase 2, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL‐108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment

Schmechel, D. E., Gerard, G., Vatakis, N. G., Harper, L., Ross, J., Bari, M. A., Walling, D. P., Stedman, M., Winston, J. L., Morimoto, B. H., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.1455 · Cited by 13 · see citing works

Improved memory with AL 108 in mild cognitive impairment

&NA; (2008) · Inpharma Weekly · doi:10.2165/00128413-200816510-00001

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

Doody, R. S., Si, G., Sano, M. C., Thomas, R. G., Aisen, P. S. S., Бачурин, С. О., Seely, L., & Hung, D. S.-Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460 · see citing works

P4‐201: A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2A CLINICAL TRIAL OF NA‐831 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT

Tran, B. H., & Tran, L. L. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.07.022

Multicenter research on efficacy and tolerance of memantine in Chinese patients with Alzheimer's disease

Tang, H. (2007)